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Introduction
This document is a compilation of the current American
College of Cardiology Foundation/American Heart Asso-ciation (ACCF/AHA) practice guideline recommendations
for atrial fibrillation (AF) from the “ACC/AHA/ESC 2006
Guidelines for the Management of Patients With Atrial
Fibrillation),”* the “2011 ACCF/AHA/HRS Focused Up-
date on the Management of Patients With Atrial Fibrilla-
tion (Updating the 2006 Guideline)”† and the “2011
ACCF/AHA/HRS Focused Update on the Management
of Patients With Atrial Fibrillation (Update on Dabiga-
tran).”‡ Updated and new recommendations from 2011 are
noted and outdated recommendations have been removed. No
new evidence was reviewed, and no recommendations included
herein are original to this document. The ACCF/AHA Task
Force on Practice Guidelines chooses to republish the recom-
mendations in this format to provide the complete set of
practice guideline recommendations in a single resource.
1. Management
1.1. Pharmacological and Nonpharmacological
Therapeutic Options
1.1.1. Rate Control During AF
CLASS I
1. Measurement of the heart rate at rest and control of the rate
using pharmacological agents (either a beta blocker or nondihy-
dropyridine calcium channel antagonist, in most cases) are
recommended for patients with persistent or permanent AF.
(Level of Evidence: B)
2. In the absence of preexcitation, intravenous administration of
beta blockers (esmolol, metoprolol, or propranolol) or nondihy-
dropyridine calcium channel antagonists (verapamil, diltiazem)
is recommended to slow the ventricular response to AF in the
acute setting, exercising caution in patients with hypotension or
heart failure (HF). (Level of Evidence: B)
3. Intravenous administration of digoxin or amiodarone is recom-
mended to control the heart rate in patients with AF and HF who
do not have an accessory pathway. (Level of Evidence: B)
4. In patients who experience symptoms related to AF during
activity, the adequacy of heart rate control should be assessed
during exercise, adjusting pharmacological treatment as neces-
*J Am Coll Cardiol. 2006;48:854-906. doi:10.1016/j.jacc.2006.07.009
†J Am Coll Cardiol. 2011;57:223-42. doi:10.1016/j.jacc.2010.10.001
‡J Am Coll Cardiol. 2011;57:1330-37. doi:10.1016/j.jacc.2011.01.010
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Evidence: C)
. Digoxin is effective following oral administration to control the
heart rate at rest in patients with AF and is indicated for patients
with HF, left ventricular (LV) dysfunction, or for sedentary
individuals. (Level of Evidence: C)
CLASS IIa
1. A combination of digoxin and either a beta blocker or nondihy-
dropyridine calcium channel antagonist is reasonable to control
the heart rate both at rest and during exercise in patients with
AF. The choice of medication should be individualized and the
dose modulated to avoid bradycardia. (Level of Evidence: B)
2. It is reasonable to use ablation of the atrioventricular (AV) node
or accessory pathway to control heart rate when pharmacologi-
cal therapy is insufficient or associated with side effects. (Level
of Evidence: B)
3. Intravenous amiodarone can be useful to control the heart rate in
patients with AF when other measures are unsuccessful or
contraindicated. (Level of Evidence: C)
4. When electrical cardioversion is not necessary in patients with
AF and an accessory pathway, intravenous procainamide or
ibutilide is a reasonable alternative. (Level of Evidence: C)
CLASS IIb
1. When the ventricular rate cannot be adequately controlled both
at rest and during exercise in patients with AF using a beta
blocker, nondihydropyridine calcium channel antagonist, or
digoxin, alone or in combination, oral amiodarone may be admin-
istered to control the heart rate. (Level of Evidence: C)
2. Intravenous procainamide, disopyramide, ibutilide, or amioda-
rone may be considered for hemodynamically stable patients
with AF involving conduction over an accessory pathway. (Level
of Evidence: B)
3. When the rate cannot be controlled with pharmacological agents
or tachycardia-mediated cardiomyopathy is suspected, catheter-
directed ablation of the AV node may be considered in patients
with AF to control the heart rate. (Level of Evidence: C)
CLASS III
1. Digitalis should not be used as the sole agent to control the rate
of ventricular response in patients with paroxysmal AF. (Level of
Evidence: B)
2. Catheter ablation of the AV node should not be attempted
without a prior trial of medication to control the ventricular rate
in patients with AF. (Level of Evidence: C)
3. In patients with decompensated HF and AF, intravenous admin-
istration of a nondihydropyridine calcium channel antagonist may
exacerbate hemodynamic compromise and is not recommended.
(Level of Evidence: C)
4. Intravenous administration of digitalis glycosides or nondihydro-
pyridine calcium channel antagonists to patients with AF and a
preexcitation syndrome may paradoxically accelerate the ven-
tricular response and is not recommended. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. 2011 New Recommendation: Treatment to achieve strict rate
control of heart rate (80 bpm at rest or 110 bpm during a
6-minute walk) is not beneficial compared to achieving a resting
heart rate 110 bpm in patients with persistent AF who have
stable ventricular function (LV ejection fraction 0.40) and no or
acceptable symptoms related to the arrhythmia, though uncon-trolled tachycardia may over time be associated with a reversible
decline in ventricular performance. (Level of Evidence: B)
1.1.2. Preventing Thromboembolism
CLASS I
1. Antithrombotic therapy to prevent thromboembolism is recom-
mended for all patients with AF, except those with lone AF or
contraindications. (Level of Evidence: A)
2. The selection of the antithrombotic agent should be based upon
the absolute risks of stroke and bleeding and the relative risk
and benefit for a given patient. (Level of Evidence: A)
3. For patients without mechanical heart valves at high risk of
stroke, chronic oral anticoagulant therapy with a vitamin K
antagonist is recommended in a dose adjusted to achieve the
target intensity international normalized ratio (INR) of 2.0 to 3.0,
unless contraindicated. Factors associated with highest risk for
stroke in patients with AF are prior thromboembolism (stroke,
transient ischemic attack, or systemic embolism) and rheumatic
mitral stenosis. (Level of Evidence: A)
4. Anticoagulation with a vitamin K antagonist is recommended for
patients with more than 1 moderate risk factor. Such factors
include age 75 y or greater, hypertension, HF, impaired LV
systolic function (ejection fraction 35% or less or fractional
shortening less than 25%), and diabetes mellitus. (Level of
Evidence: A)
5. INR should be determined at least weekly during initiation of
therapy and monthly when anticoagulation is stable. (Level of
Evidence: A)
6. Aspirin, 81–325 mg daily, is recommended as an alternative to
vitamin K antagonists in low-risk patients or in those with
contraindications to oral anticoagulation. (Level of Evidence: A)
7. For patients with AF who have mechanical heart valves, the
target intensity of anticoagulation should be based on the type of
prosthesis, maintaining an INR of at least 2.5. (Level of Evi-
dence: B)
8. Antithrombotic therapy is recommended for patients with atrial
flutter as for those with AF. (Level of Evidence: C)
CLASS IIa
1. For primary prevention of thromboembolism in patients with
nonvalvular AF who have just 1 of the following validated risk
factors, antithrombotic therapy with either aspirin or a vitamin K
antagonist is reasonable, based upon an assessment of the risk
of bleeding complications, ability to safely sustain adjusted
chronic anticoagulation, and patient preferences: age greater
than or equal to 75 y (especially in female patients), hyperten-
sion, HF, impaired LV function, or diabetes mellitus. (Level of
Evidence: A)
2. For patients with nonvalvular AF who have 1 or more of the
following less well-validated risk factors, antithrombotic therapy
with either aspirin or a vitamin K antagonist is reasonable for
prevention of thromboembolism: age 65 to 74 y, female gender,
or coronary artery disease. The choice of agent should be based
upon the risk of bleeding complications, ability to safely sustain
adjusted chronic anticoagulation, and patient preferences.
(Level of Evidence: B)
3. It is reasonable to select antithrombotic therapy using the same
criteria irrespective of the pattern (i.e., paroxysmal, persistent,
or permanent) of AF. (Level of Evidence: B)
AA
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valves, it is reasonable to interrupt anticoagulation for up to 1
week without substituting heparin for surgical or diagnostic
procedures that carry a risk of bleeding. (Level of Evidence: C)
5. It is reasonable to reevaluate the need for anticoagulation at
regular intervals. (Level of Evidence: C)
CLASS IIb
1. In patients 75 y of age and older at increased risk of bleeding but
without frank contraindications to oral anticoagulant therapy,
and in other patients with moderate risk factors for thromboem-
bolism who are unable to safely tolerate anticoagulation at the
standard intensity of INR 2.0 to 3.0, a lower INR target of 2.0
(range 1.6 to 2.5) may be considered for primary prevention of
ischemic stroke and systemic embolism. (Level of Evidence: C)
2. When surgical procedures require interruption of oral anticoagu-
lant therapy for longer than 1 week in high-risk patients, unfrac-
tionated heparin may be administered or low-molecular-weight
heparin given by subcutaneous injection, although the efficacy of
these alternatives in this situation is uncertain. (Level of Evi-
dence: C)
3. Following percutaneous coronary intervention or revasculariza-
tion surgery in patients with AF, low-dose aspirin (less than 100
mg per d) and/or clopidogrel (75 mg per d) may be given
concurrently with anticoagulation to prevent myocardial isch-
emic events, but these strategies have not been thoroughly
evaluated and are associated with an increased risk of bleeding.
(Level of Evidence: C)
4. In patients undergoing percutaneous coronary intervention, an-
ticoagulation may be interrupted to prevent bleeding at the site
of peripheral arterial puncture, but the vitamin K antagonist
should be resumed as soon as possible after the procedure and
the dose adjusted to achieve an INR in the therapeutic range.
Aspirin may be given temporarily during the hiatus, but the
maintenance regimen should then consist of the combination of
clopidogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0). Clopi-
dogrel should be given for a minimum of 1 mo after implantation
of a bare metal stent, at least 3 mo for a sirolimus-eluting stent,
at least 6 mo for a paclitaxel-eluting stent, and 12 mo or longer
in selected patients, following which warfarin may be continued
as monotherapy in the absence of a subsequent coronary event.
When warfarin is given in combination with clopidogrel or low-
dose aspirin, the dose intensity must be carefully regulated.
(Level of Evidence: C)
5. In patients with AF younger than 60 y without heart disease or
risk factors for thromboembolism (lone AF), the risk of thrombo-
embolism is low without treatment and the effectiveness of
aspirin for primary prevention of stroke relative to the risk of
bleeding has not been established. (Level of Evidence: C)
6. In patients with AF who sustain ischemic stroke or systemic
embolism during treatment with low-intensity anticoagulation
(INR 2.0 to 3.0), rather than add an antiplatelet agent, it may be
reasonable to raise the intensity of anticoagulation to a maxi-
mum target INR of 3.0 to 3.5. (Level of Evidence: C)
CLASS III
1. Long-term anticoagulation with a vitamin K antagonist is not
recommended for primary prevention of stroke in patients below
the age of 60 y without heart disease (lone AF) or any risk
factors for thromboembolism. (Level of Evidence: C)1.1.2.1. ANTITHROMBOTIC STRATEGIES FOR PREVENTION OF
ISCHEMIC STROKE AND SYSTEMIC EMBOLISM
1.1.2.1.1. COMBINING ANTICOAGULANT WITH
NTIPLATELET THERAPY (2011 NEW SECTION)
CLASS IIb
1. 2011 New Recommendation: The addition of clopidogrel to
aspirin to reduce the risk of major vascular events, including
stroke, might be considered in patients with AF in whom oral
anticoagulation with warfarin is considered unsuitable due to
patient preference or the physician’s assessment of the pa-
tient’s ability to safely sustain anticoagulation. (Level of Evi-
dence: B)
1.1.2.1.2. USE OF ORAL DIRECT THROMBIN INHIBITOR
NTICOAGULANT AGENTS (2011 NEW SECTION)
CLASS I
1. 2011 New Recommendation: Dabigatran is useful as an alterna-
tive to warfarin for the prevention of stroke and systemic
thromboembolism in patients with paroxysmal to permanent AF
and risk factors for stroke or systemic embolization who do not
have a prosthetic heart valve or hemodynamically significant
valve disease, severe renal failure (creatinine clearance 15
mL/min) or advanced liver disease (impaired baseline clotting
function). (Level of Evidence: B)
1.1.3. Cardioversion of AF
CLASS I
1. Administration of flecainide, dofetilide, propafenone, or ibutilide
is recommended for pharmacological cardioversion of AF. (Level
of Evidence: A)
CLASS IIa
1. Administration of amiodarone is a reasonable option for pharma-
cological cardioversion of AF. (Level of Evidence: A)
2. A single oral bolus dose of propafenone or flecainide (“pill-in-the-
pocket”) can be administered to terminate persistent AF outside
the hospital once treatment has proved safe in hospital for
selected patients without sinus or AV node dysfunction, bundle-
branch block, QT-interval prolongation, the Brugada syndrome, or
structural heart disease. Before antiarrhythmic medication is
initiated, a beta blocker or nondihydropyridine calcium channel
antagonist should be given to prevent rapid AV conduction in the
event atrial flutter occurs. (Level of Evidence: C)
3. Administration of amiodarone can be beneficial on an outpatient
basis in patients with paroxysmal or persistent AF when rapid
restoration of sinus rhythm is not deemed necessary. (Level of
Evidence: C)
CLASS IIb
1. Administration of quinidine or procainamide might be considered
for pharmacological cardioversion of AF, but the usefulness of
these agents is not well established. (Level of Evidence: C)
CLASS III
1. Digoxin and sotalol may be harmful when used for pharmacolog-
ical cardioversion of AF and are not recommended. (Level of
Evidence: A)
2. Quinidine, procainamide, disopyramide, and dofetilide should not
be started out of hospital for conversion of AF to sinus rhythm.
(Level of Evidence: B)
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(2011 NEW SECTION)
CLASS IIa
1. 2011 New Recommendation: Dronedarone is reasonable to de-
crease the need for hospitalization for cardiovascular events in
patients with paroxysmal AF or after conversion of persistent AF.
Dronedarone can be initiated during outpatient therapy. (Level of
Evidence: B)
CLASS III: HARM
1. 2011 New Recommendation: Dronedarone should not be admin-
istered to patients with class IV heart failure or patients who
have had an episode of decompensated heart failure in the past
4 weeks, especially if they have depressed left ventricular
function (left ventricular ejection fraction <35%). (Level of
Evidence: B)
1.2. Direct-Current Cardioversion of AF and Flutter
CLASS I
1. When a rapid ventricular response does not respond promptly to
pharmacological measures for patients with AF with ongoing
myocardial ischemia, symptomatic hypotension, angina, or HF,
immediate R-wave synchronized direct-current cardioversion is
recommended. (Level of Evidence: C)
2. Immediate direct-current cardioversion is recommended for pa-
tients with AF involving preexcitation when very rapid tachycar-
dia or hemodynamic instability occurs. (Level of Evidence: B)
3. Cardioversion is recommended in patients without hemody-
namic instability when symptoms of AF are unacceptable to
the patient. In case of early relapse of AF after cardioversion,
repeated direct-current cardioversion attempts may be made
following administration of antiarrhythmic medication. (Level
of Evidence: C)
CLASS IIa
1. Direct-current cardioversion can be useful to restore sinus
rhythm as part of a long-term management strategy for patients
with AF. (Level of Evidence: B)
2. Patient preference is a reasonable consideration in the selection
of infrequently repeated cardioversions for the management of
symptomatic or recurrent AF. (Level of Evidence: C)
CLASS III
1. Frequent repetition of direct-current cardioversion is not recom-
mended for patients who have relatively short periods of sinus
rhythm between relapses of AF after multiple cardioversion
procedures despite prophylactic antiarrhythmic drug therapy.
(Level of Evidence: C)
2. Electrical cardioversion is contraindicated in patients with digi-
talis toxicity or hypokalemia. (Level of Evidence: C)
1.2.1. Pharmacological Enhancement of
Direct-Current Cardioversion
CLASS IIa
1. Pretreatment with amiodarone, flecainide, ibutilide, propafenone, or
sotalol can be useful to enhance the success of direct-current
cardioversion and prevent recurrent atrial fibrillation. (Level of
Evidence: B)
2. In patients who relapse to AF after successful cardioversion,
it can be useful to repeat the procedure following prophylactic
administration of antiarrhythmic medication. (Level of Evi-
dence: C)CLASS IIb
1. For patients with persistent AF, administration of beta blockers,
disopyramide, diltiazem, dofetilide, procainamide, or verapamil
may be considered, although the efficacy of these agents to
enhance the success of direct-current cardioversion or to pre-
vent early recurrence of AF is uncertain. (Level of Evidence: C)
2. Out-of-hospital initiation of antiarrhythmic medications may be
considered in patients without heart disease to enhance the
success of cardioversion of AF. (Level of Evidence: C)
3. Out-of-hospital administration of antiarrhythmic medications may
be considered to enhance the success of cardioversion of AF in
patients with certain forms of heart disease once the safety of
the drug has been verified for the patient. (Level of Evidence: C)
1.2.2. Prevention of Thromboembolism in Patients
With AF Undergoing Cardioversion
CLASS I
1. For patients with AF of 48-hour duration or longer, or when the
duration of AF is unknown, anticoagulation (INR 2.0 to 3.0) is
recommended for at least 3 wk prior to and 4 wk after cardio-
version, regardless of the method (electrical or pharmacological)
used to restore sinus rhythm. (Level of Evidence: B)
2. For patients with AF of more than 48-h duration requiring
immediate cardioversion because of hemodynamic instability,
heparin should be administered concurrently (unless contraindi-
cated) by an initial intravenous bolus injection followed by a
continuous infusion in a dose adjusted to prolong the activated
partial thromboplastin time to 1.5 to 2 times the reference
control value. Thereafter, oral anticoagulation (INR 2.0 to 3.0)
should be provided for at least 4 wk, as for patients undergoing
elective cardioversion. Limited data support subcutaneous ad-
ministration of low-molecular-weight heparin in this indication.
(Level of Evidence: C)
3. For patients with AF of less than 48-h duration associated with
hemodynamic instability (angina pectoris, myocardial infarction
(MI), shock, or pulmonary edema), cardioversion should be
performed immediately without delay for prior initiation of anti-
coagulation. (Level of Evidence: C)
CLASS IIa
1. During the first 48 h after onset of AF, the need for anticoagu-
lation before and after cardioversion may be based on the
patient’s risk of thromboembolism. (Level of Evidence: C)
2. As an alternative to anticoagulation prior to cardioversion of AF,
it is reasonable to perform transesophageal echocardiogram in
search of thrombus in the left atrium or left atrium appendage.
(Level of Evidence: B)
2a. For patients with no identifiable thrombus, cardioversion is
reasonable immediately after anticoagulation with unfrac-
tionated heparin (e.g., initiate by intravenous bolus injection
and an infusion continued at a dose adjusted to prolong the
activated partial thromboplastin time to 1.5 to 2 times the
control value until oral anticoagulation has been established
with a vitamin K antagonist (e.g., warfarin), as evidenced by
an INR equal to or greater than 2.0.) (Level of Evidence: B).
Thereafter, continuation of oral anticoagulation (INR 2.0 to
3.0) is reasonable for a total anticoagulation period of at
least 4 wk, as for patients undergoing elective cardioversion
(Level of Evidence: B). Limited data are available to support
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heparin in this indication. (Level of Evidence: C)
2b. For patients in whom thrombus is identified by transesopha-
geal echocardiogram, oral anticoagulation (INR 2.0 to 3.0)
is reasonable for at least 3 wk prior to and 4 wk after
restoration of sinus rhythm, and a longer period of anticoag-
ulation may be appropriate even after apparently successful
cardioversion, because the risk of thromboembolism often
remains elevated in such cases. (Level of Evidence: C)
. For patients with atrial flutter undergoing cardioversion, antico-
agulation can be beneficial according to the recommendations
as for patients with AF. (Level of Evidence: C)
1.3. Maintenance of Sinus Rhythm
CLASS I
1. Before initiating antiarrhythmic drug therapy, treatment of pre-
cipitating or reversible causes of AF is recommended. (Level of
Evidence: C)
2. 2011 Updated Recommendation: Catheter ablation performed in
experienced centers§ is useful in maintaining sinus rhythm in
selected patients with significantly symptomatic, paroxysmal AF
who have failed treatment with an antiarrhythmic drug and have
normal or mildly dilated left atria, normal or mildly reduced LV
function, and no severe pulmonary disease. (Level of Evidence: A)
CLASS IIa
1. Pharmacological therapy can be useful in patients with AF to
maintain sinus rhythm and prevent tachycardia-induced cardio-
myopathy. (Level of Evidence: C)
2. Infrequent, well-tolerated recurrence of AF is reasonable as a
successful outcome of antiarrhythmic drug therapy. (Level of
Evidence: C)
3. Outpatient initiation of antiarrhythmic drug therapy is reasonable
in patients with AF who have no associated heart disease when
the agent is well tolerated. (Level of Evidence: C)
4. 2011 Updated Recommendation: In patients with AF without
structural or coronary heart disease, initiation of propafenone or
flecainide can be beneficial on an outpatient basis in patients
with paroxysmal AF who are in sinus rhythm at the time of drug
initiation. (Level of Evidence: B)
5. Sotalol can be beneficial in outpatients in sinus rhythm with little
or no heart disease, prone to paroxysmal AF, if the baseline
uncorrected QT interval is less than 460 ms, serum electrolytes
are normal, and risk factors associated with class III drug–
related proarrhythmia are not present. (Level of Evidence: C)
6. 2011 New Recommendation: Catheter ablation is reasonable to
treat symptomatic persistent AF. (Level of Evidence: A)
CLASS IIb
1. 2011 New Recommendation: Catheter ablation may be reason-
able to treat symptomatic paroxysmal AF in patients with
significant left atrial dilatation or with significant LV dysfunction.
(Level of Evidence: A)
§Refers to pulmonary vein isolation with catheter ablation. An experienced center is
defined as one performing more than 50 AF catheter ablation cases per year.
Evidence-based technical guidelines including operator training and experience
necessary to maximize rates of successful catheter ablation are not available; each
center should maintain a database detailing procedures; success and complications,
engage strategies for continuous quality improvement, and participate in registries and
other efforts pooling data in order to develop optimal care algorithms.CLASS III: HARM
1. Antiarrhythmic therapy with a particular drug is not recom-
mended for maintenance of sinus rhythm in patients with AF who
have well-defined risk factors for proarrhythmia with that agent.
(Level of Evidence: A)
2. Pharmacological therapy is not recommended for maintenance of
sinus rhythm in patients with advanced sinus node disease or AV
node dysfunction unless they have a functioning electronic
cardiac pacemaker. (Level of Evidence: C)
1.4. Special Considerations
1.4.1. Postoperative AF
CLASS I
1. Unless contraindicated, treatment with an oral beta blocker to
prevent postoperative AF is recommended for patients undergo-
ing cardiac surgery. (Level of Evidence: A)
2. Administration of AV nodal blocking agents is recommended to
achieve rate control in patients who develop postoperative AF.
(Level of Evidence: B)
CLASS IIa
1. Preoperative administration of amiodarone reduces the inci-
dence of AF in patients undergoing cardiac surgery and repre-
sents appropriate prophylactic therapy for patients at high risk
for postoperative AF. (Level of Evidence: A)
2. It is reasonable to restore sinus rhythm by pharmacological
cardioversion with ibutilide or direct-current cardioversion in
patients who develop post-operative AF as advised for nonsurgi-
cal patients. (Level of Evidence: B)
3. It is reasonable to administer antiarrhythmic medications in an
attempt to maintain sinus rhythm in patients with recurrent or
refractory postoperative AF, as recommended for other patients
who develop AF. (Level of Evidence: B)
4. It is reasonable to administer antithrombotic medication in
patients who develop postoperative AF, as recommended for
nonsurgical patients. (Level of Evidence: B)
CLASS IIb
1. Prophylactic administration of sotalol may be considered for
patients at risk of developing AF following cardiac surgery. (Level
of Evidence: B)
1.4.2. Acute Myocardial Infarction
CLASS I
1. Direct-current cardioversion is recommended for patients with
severe hemodynamic compromise or intractable ischemia, or
when adequate rate control cannot be achieved with pharmaco-
logical agents in patients with acute MI and AF. (Level of
Evidence: C)
2. Intravenous administration of amiodarone is recommended to
slow a rapid ventricular response to AF and improve LV function
in patients with acute MI. (Level of Evidence: C)
3. Intravenous beta blockers and nondihydropyridine calcium antag-
onists are recommended to slow a rapid ventricular response to
AF in patients with acute MI who do not display clinical LV
dysfunction, bronchospasm, or AV block. (Level of Evidence: C)
4. For patients with AF and acute MI, administration of unfraction-
ated heparin by either continuous intravenous infusion or inter-
mittent subcutaneous injection is recommended in a dose suffi-
cient to prolong the activated partial thromboplastin time to 1.5
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anticoagulation exist. (Level of Evidence: C)
CLASS IIa
1. Intravenous administration of digitalis is reasonable to slow a
rapid ventricular response and improve LV function in patients
with acute MI and AF associated with severe LV dysfunction and
HF. (Level of Evidence: C)
CLASS III
1. The administration of class IC antiarrhythmic drugs is not
recommended in patients with AF in the setting of acute MI.
(Level of Evidence: C)
1.4.3. Wolff-Parkinson-White Preexcitation Syndromes
CLASS I
1. Catheter ablation of the accessory pathway is recommended in
symptomatic patients with AF who have Wolff-Parkinson-White
Preexcitation syndrome, particularly those with syncope due to
rapid heart rate or those with a short bypass tract refractory
period. (Level of Evidence: B)
2. Immediate direct-current cardioversion is recommended to pre-
vent ventricular fibrillation in patients with a short anterograde
bypass tract refractory period in whom AF occurs with a rapid
ventricular response associated with hemodynamic instability.
(Level of Evidence: B)
3. Intravenous procainamide or ibutilide is recommended to restore
sinus rhythm in patients with Wolff-Parkinson-White Preexcita-
tion in whom AF occurs without hemodynamic instability in
association with a wide QRS complex on the electrocardiogram
(greater than or equal to 120-ms duration) or with a rapid
preexcited ventricular response. (Level of Evidence: C)
CLASS IIa
1. Intravenous flecainide or direct-current cardioversion is reasonable
when very rapid ventricular rates occur in patients with AF involving
conduction over an accessory pathway. (Level of Evidence: B)
CLASS IIb
1. It may be reasonable to administer intravenous quinidine, pro-
cainamide, disopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
CLASS III
1. Intravenous administration of digitalis glycosides or nondihydro-
pyridine calcium channel antagonists is not recommended in
patients with WPW syndrome who have preexcited ventricular
activation during AF. (Level of Evidence: B)
1.4.4. Hyperthyroidism
CLASS I
1. Administration of a beta blocker is recommended to control the
rate of ventricular response in patients with AF complicating
thyrotoxicosis, unless contraindicated. (Level of Evidence: B)
2. In circumstances when a beta blocker cannot be used, adminis-
tration of a nondihydropyridine calcium channel antagonist (dil-
tiazem or verapamil) is recommended to control the ventricular
rate in patients with AF and thyrotoxicosis. (Level of Evidence: B)
3. In patients with AF associated with thyrotoxicosis, oral antico-
agulation (INR 2.0 to 3.0) is recommended to prevent thrombo-
embolism, as recommended for AF patients with other risk
factors for stroke. (Level of Evidence: C)4. Once a euthyroid state is restored, recommendations for anti-
thrombotic prophylaxis are the same as for patients without
hyperthyroidism. (Level of Evidence: C)
1.4.5. Pregnancy
CLASS I
1. Digoxin, a beta blocker, or a nondihydropyridine calcium channel
antagonist is recommended to control the rate of ventricular
response in pregnant patients with AF. (Level of Evidence: C)
2. Direct-current cardioversion is recommended in pregnant pa-
tients who become hemodynamically unstable due to AF. (Level
of Evidence: C)
3. Protection against thromboembolism is recommended through-
out pregnancy for all patients with AF (except those with lone AF
and/or low thromboembolic risk). Therapy (anticoagulant or
aspirin) should be chosen according to the stage of pregnancy.
(Level of Evidence: C)
CLASS IIb
1. Administration of heparin may be considered during the first
trimester and last month of pregnancy for patients with AF and
risk factors for thromboembolism. Unfractionated heparin may be
administered either by continuous intravenous infusion in a dose
sufficient to prolong the activated partial thromboplastin time to
1.5 to 2 times the control value or by intermittent subcutaneous
injection in a dose of 10,000 to 20,000 units every 12 h,
adjusted to prolong the mid-interval (6 h after injection) acti-
vated partial thromboplastin time to 1.5 times control. (Level of
Evidence: B)
2. Despite the limited data available, subcutaneous administration
of low-molecular-weight heparin may be considered during the
first trimester and last month of pregnancy for patients with AF
and risk factors for thromboembolism. (Level of Evidence: C)
3. Administration of an oral anticoagulant may be considered during
the second trimester for pregnant patients with AF at high
thromboembolic risk. (Level of Evidence: C)
4. Administration of quinidine or procainamide may be considered to
achieve pharmacological cardioversion in hemodynamically stable
patients who develop AF during pregnancy. (Level of Evidence: C)
1.4.6. Hypertrophic Cardiomyopathy
CLASS I
1. Oral anticoagulation (INR 2.0 to 3.0) is recommended in patients
with hypertrophic cardiomyopathy who develop AF, as for other
patients at high risk of thromboembolism. (Level of Evidence: B)
CLASS IIa
1. Antiarrhythmic medications can be useful to prevent recurrent
AF in patients with hypertrophic cardiomyopathy. Available data
are insufficient to recommend one agent over another in this
situation, but (a) disopyramide combined with a beta blocker or
nondihydropyridine calcium channel antagonist or (b) amioda-
rone alone is generally preferred. (Level of Evidence: C)
1.4.7. Pulmonary Diseases
CLASS I
1. Correction of hypoxemia and acidosis is the recommended
primary therapeutic measure for patients who develop AF during
an acute pulmonary illness or exacerbation of chronic pulmonary
disease. (Level of Evidence: C)
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verapamil) is recommended to control the ventricular rate in
patients with obstructive pulmonary disease who develop AF.
(Level of Evidence: C)
3. Direct-current cardioversion should be attempted in patients
with pulmonary disease who become hemodynamically unstable
as a consequence of AF. (Level of Evidence: C)CLASS III
1. Theophylline and beta-adrenergic agonist agents are not recom-
mended in patients with bronchospastic lung disease who de-
velop AF. (Level of Evidence: C)
2. Beta blockers, sotalol, propafenone, and adenosine are not
recommended in patients with obstructive lung disease who
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